Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

European Journal of Neuroscience

Volumn 14, Issue 11, 2001, Pages 1827-1832

  Lastres Becker, I ^a   Cebeira, M ^a   De Ceballos, M L ^b   Zeng, B Y ^c   Jenner, P ^c   Ramos, J A ^a   Fernández Ruiz, Javier J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO CAJAL   (Spain)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Basal ganglia; CB1 receptor; Common marmosets; Humans; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); LEVODOPA; CANNABINOID RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CONTROLLED STUDY; FEMALE; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; MALE; MARMOSET; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BLOCKING; RECEPTOR DENSITY; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; ANIMAL; BINDING COMPETITION; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MIDDLE AGED; NERVE CELL; PARKINSONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; UPREGULATION;

AGED; AGED, 80 AND OVER; ANIMALS; BASAL GANGLIA; BINDING, COMPETITIVE; CALLITHRIX; DOPAMINE AGENTS; FEMALE; GTP-BINDING PROTEINS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NEURONS; PARKINSONIAN DISORDERS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; UP-REGULATION;

EID: 0035545362     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0953-816X.2001.01812.x     Document Type: Article

References (42)

1. Anderson, L.A., Anderson, J.J., Chase, T.N. & Walters, J.R. (1995) The cannabinoid agonists WIN 55,212-2 and CP 55, 940 attenuate rotational behaviour induced by a dopamine D1 but not D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Res. 691, 106-114.
2. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J. Neurochem., 73, 2447-2459.
3. Breivogel, C.S., Sim, L.J. & Childers, S.R. (1997) Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther., 282, 1632-1642.
4. Brotchie, J.M. (1998) Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord., 13, 871-876.
5. Chan, P.K., Chan, S.C. & Yung, W.H. (1998) Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist. Neuroreport, 9, 671-675.
6. Consroe, P. (1998) Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol. Dis., 5, 534-551.
7. Crawley, J.N., Corvin, R.L., Robinson, J.K., Felder, C.C., Devane, W. & Axelrod, J. (1993) Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav., 46, 967-972.
8. Dexter, D.T., Carter, C.J., Wells, F.R., Javoy-Agid, F., Agid, Y., Lees, A., Jenner, P. & Marsden, C.D. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem., 52, 381-389.
9. Di Marzo, V., Hill, M.P., Bisogno, T., Crossman, A.R. & Brotchie, J.M. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J., 14, 1432-1438.
10. Fride, E. & Mechoulam, R. (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacol., 231, 313-314.
11. Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodriguez de Fonseca, F., Navarro, M. & Piomelli, D. (1999) Dopamine activation of endogenous signaling in dorsal striatum. Nature Neurosci., 2, 358-363.
12. Herkenham, M., Lynn, A.B., de Costa, B.R. & Richfield, E.K. (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res., 547, 267-274.
13. 3H]-CP-55,940 binding to the cannabinoid receptor. Du Pont Biotech. Update, 6, 21-27.
14. Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
15. Mailleux, P. & Vanderhaeghen, J.J. (1992) Distribution of neuronal cannabinoid receptor in the adult brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience, 48, 655-668.
16. Mailleux, P. & Vanderhaeghen, J.J. (1993) Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study. J. Neurochem., 61, 1705-1712.
17. Mailleux, P. & Vanderhaeghen, J.J. (1994) Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur. J. Pharmacol., 266, 193-196.
18. Maneuf, Y.P., Crossman, A.R. & Brotchie, J.M. (1996a) Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse, 22, 382-385.
19. Maneuf, Y.P., Crossman, A.R. & Brotchie, J.M. (1997) The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol., 148, 265-270.
20. Maneuf, Y.P., Nash, J.E., Crossman, A.R. & Brotchie, J.M. (1996b) Activation of the cannabinoid receptor by delta-9-tetrahydrocannabinol reduces GABA uptake in the globus pallidus. Eur. J. Pharmacol., 308, 161-164.
21. Miller, A.S., Sañudo-Peña, M.C. & Walker, J.M. (1998) Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus. Brain Res., 793, 7-11.
22. Pearce, R.K.B., Jackson, M., Smith, L., Jenner, P. & Marsden, C.D. (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated marmoset (Callithrix jacchus). Mov. Disord., 10, 731-740.
23. 35S]-guanylyl-5′-[γ-thio]-triphosphate binding in the basal ganglia of aged rats. Neuroscience, 84, 1075-1083.
24. 1 receptor mRNA levels in the caudate-putamen. Life Sci., 66, 485-494.
25. Romero, J., de Miguel, R., García-Palomero, E., Fernández-Ruiz, J.J. & Ramos, J.A. (1995b) Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res., 694, 223-232.
26. Romero, J., García, L., Cebeira, M., Zadrozny, D., Fernández-Ruiz, J.J. & Ramos, J.A. (1995a) The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: Role of nigrostriatal dopaminergic neurons. Life Sci., 56, 2033-2040.
27. Romero, J., de Miguel, R., Ramos, J.A. & Fernández-Ruiz, J.J. (1998a) The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake. Life Sci., 62, 351-363.
28. Sañudo-Peña, M.C., Force, M., Tsou, K., Miller, A.S. & Walker, J.M. (1998a) Effects of intrastriatal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Synapse, 30, 221-226.
29. Sañudo-Peña, M.C., Patrick, S.L., Khen, S., Patrick, R.L. & Walker, J.M. (1998b) Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci. Lett., 248, 171-174.
30. Sañudo-Peña, M.C., Patrick, S.L., Patrick, R.L. & Walker, J.M. (1996) Effects of intranigral cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Neurosci. Lett., 206, 21-24.
31. Sañudo-Peña, M.C., Romero, J., Seale, G.E., Fernández-Ruiz, J.J. & Walker, J.M. (2000) Activational role of cannabinoids on movement. Eur. J. Pharmacol., 391, 269-274.
32. Sañudo-Peña, M.C. & Walker, J.M. (1997) Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J. Neurophysiol., 77, 1635-1638.
33. Sañudo-Peña, M.C. & Walker, J.M. (1998) Effects of intrapallidal cannabinoids on rotational behavior in rats: Interactions with the dopaminergic system. Synapse, 28, 27-32.
34. Silverdale, M.A., McGuire, D., McInnes, A., Crossman, A.R. & Brotchie, J.M. (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp. Neurol., 169, 400-406.
35. 35S]thio]-triphosphate binding. Proc. Natl. Acad. Sci. USA, 92, 7242-7246.
36. Smith, P.B., Compton, D.R., Welch, S.P., Razdan, R.K., Mechoulam, R. & Martin, B.R. (1994) The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther., 270, 219-227.
37. Stephan, H., Baron, G. & Schwerdtferger, W.K. (1980) The Brain of the Common Marmoset (Callithrix Jacchus). Springer-Verlag, Berlin.
38. Szabo, B., Wallmichrath, I., Mathonia, P. & Pfreundther, C. (2000) Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata. Neuroscience, 97, 89-97.
39. 35S]thio) triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol., 47, 848-854.
40. Tsou, K., Brown, S., Sañudo-Peña, M.C., Mackie, K. & Walker, J.M. (1998) Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience, 83, 393-411.
41. 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats. Eur. J. Pharmacol., 250, 205-208.
42. Zeng, B.Y., Dass, B., Owen, A., Rose, S., Cannizzaro, C., Tel, B.C. & Jenner, P. (1999) Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett., 276, 71-74.